


# Association Between Postoperative Troponin Levels and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery

The Vascular Events In Noncardiac  
Surgery Patients Cohort Evaluation  
(VISION) Study Investigators





**Patient Recruitment**



30-  
 2-  
 30-  
 1000  
 30-  
 1000  
 30-  
 1000  
 30-  
 1000

( $\dots$ ) ( $<30$  /  $1.73^2$   
 $1.73^2$ ,  $30$   $44$  /  
 $1.73^2$ ,  $45$   $59$  /  
 $1.73^2$ ,  $\geq 60$  /  $1.73^2$   
 $^{16,17}$

30-  
 ( $\dots$ ), 95%  
 2-  
 $\alpha = .05$   
 30-  
 95%  
 1000

( $\dots$ )  
 30-  
 10,11  
 ( $\dots$ )  
 30-  
 12-14  
 1000

30-  
 1000  
 30-  
 1000  
 30-  
 1000  
 30-  
 1000

1000  
 30-  
 15  
 30-  
 ( $<1\%$ ), ( $1\%-5\%$ ),  
 ( $>5\%-10\%$ ),  
 ( $>10\%$ ).

30-  
 0.03-0.29 g/l (5.00;  
 95% 3.72-6.76) 0.30 g/l  
 (10.48; 95% 6.25-  
 16.62).  
 89.0%; 95%  
 85.3-92.4);  
 (41.8%).  
 0.01 g/l  
 , 0.02 g/l , 0.03-0.29 g/l ,  
 0.30 g/l  
 88.4%, 3.3%, 7.4%, 0.9%  
 30- 1.0%, 4.0%,  
 9.3%, 16.9%  
 0.01 , 0.02,  
 0.03-0.29, 0.30 g/l  
 3 15133

0.02 g/l (13.5 ;  
 8.5-20 ) ; 0.03-0.29 g/l (9.0  
 ; 3.5-16 ) ; 0.30 g/l  
 (6.5 ; 1.5-15 ) ,  
 =.01  
 2  
 4  
 5  
 36  
 15133

10, 88  
 =.43).  
 =0.85 0.81; , 0.4; 95%  
 , 0.2-0.5 <.001  
 ).  
 18.8% (AB 2).  
 6.2%.  
 25.0% (95%  
 , 17.2%-32.8%; <.001).  
 14 008 (92.6%)

520 (3.7%)  
 30 /  
 1.73 2 ; 760  
 (5.4%) 30  
 44 / 1.73 2




**COMMENT**

**Strengths and Limitations**

15 133  
 145  
 1.0%  $\leq 0.01$   
 4.0%  $\leq 0.02$ ; 9.3%  
 0.03-0.29  
 16.9%  $\geq 0.30$   
 11.6%  
 0.02, 0.03  
 0.30  
 30  
 30  
 41.8%

8 5  
 1.1



30- (41.8%).

0.04.

30- (<1%), (1%-5%), (>5%-10%), (>10%)

18.8% 6.2%,

10%,

10.04 g/

23,24

0.04 g/ (, 0.02 g/ 0.03 g/ )

30-

0.02 g/ (, 13.5 ) 0.03 g/ (9.0 )

25

200

45

11.6%

0.02 g/ , 10

10

10

10



ter Nagele, MD, MSc, Yannick Le Manach, MD, PhD, Martin Leuwer, MD, PhD, Salim Yusuf, MD, DPhil: The Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators.

**Author Affiliations:** are available as eAppendix 1 at <http://www.jama.com>.

**Author Contributions:** Dr Devereaux had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Chan, Walsh, Villar, Jacka, Botto, Guyatt, Thorlund, Mrkobrada, Thomas, Bhandari, Yusuf, Devereaux.

**Acquisition of data:** Chan, Alonso-Coello, Walsh, Villar, Wang, Garutti, Sigamani, Srinathan, Biccard, Chow, Abraham, Tiboni, Pettit, Szczeklik, Lurati-Buse, Botto, Mrkobrada, Thomas, Rodseth, Pearse, McQueen, VanHelder, Bosch, Polanczyk, Malaga, Nagele, Yusuf, Devereaux.

**Analysis and interpretation of data:** Chan, Alonso-Coello, Walsh, Berwanger, Villar, Wang, Szczeklik, Lurati-Buse, Botto, Heels-Ansdell, Sessler, Thorlund, Garg, Mrkobrada, Thomas, Rodseth, Pearse, Thabane, McQueen, VanHelder, Kurz, Polanczyk, LeManach, Leuwer, Yusuf, Devereaux.

**Drafting of the manuscript:** Devereaux.

**Critical revision of the manuscript for important intellectual content:** Chan, Alonso-Coello, Walsh, Berwanger, Villar, Wang, Garutti, Jacka, Sigamani, Srinathan, Biccard, Chow, Abraham, Tiboni, Szczeklik, Lurati-Buse, Botto, Guyatt, Heels-Ansdell, Sessler, Thorlund, Garg, Mrkobrada, Thomas, Rodseth, Pearse, Thabane, McQueen, Bhandari, Bosch, Kurz, Polanczyk, Malaga, Nagele, Leuwer, Yusuf, Devereaux.

**Statistical analysis:** Heels-Ansdell, Thorlund, Thabane.

**Obtained funding:** Chan, Alonso-Coello, Walsh, Wang, Srinathan, Chow, Thomas, Pearse, Bhandari, Polanczyk, Nagele, Devereaux.

**Administrative, technical, or material support:** Chan, Walsh, Berwanger, Villar, Sigamani, Srinathan, Biccard, Abraham, Szczeklik, Lurati-Buse, Botto, Mrkobrada, Rodseth, McQueen, Bosch, Leuwer, Yusuf, Devereaux.

**Study supervision:** Walsh, Garutti, Jacka, Sigamani, Biccard, Tiboni, Szczeklik, Botto, Sessler, McQueen, VanHelder, Bhandari, Malaga, Nagele, Devereaux.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Chan, Walsh, Carlos Villar, Garutti, Jacka, Srinathan, Biccard, Tiboni, Szczeklik, McQueen, VanHelder, Bhandari, Kurz, Malaga, Nagele, Leuwer, and Devereaux; and Ms Bosch report receipt of a grant(s) to their institution from Roche Diagnostics Global Office (Troponin T assays and some financial support for the VISION Study). Dr Chan reports receipt of institutional grants from the

## REFERENCES

1. Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery. *Lancet*. 2008;372(9633):139-144.
2. Devereaux PJ, Chan M, Eikelboom J. Major vascular complications in patients undergoing noncardiac surgery: the magnitude of the problem, risk prediction, surveillance, and prevention. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. *Evidence-Based Cardiology*. 3rd ed. London, England: BMJ Books; 2009:47-62.
3. Devereaux PJ, Yang H, Yusuf S, et al; POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial). *Lancet*. 2008;371(9627):1839-1847.
4. Ford MK, Beattie WS, Wijeyesundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. *Ann Intern Med*. 2010;152(1):26-35.
5. Gordon HS, Johnson ML, Wray NP, et al. Mortality after noncardiac surgery: prediction from administrative versus clinical data. *Med Care*. 2005;43(2):159-167.
6. Kim LJ, Martinez EA, Faraday N, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. *Circulation*. 2002;106(18):2366-2371.
7. Le Manach Y, Perel A, Coriat P, Godet G, Bertrand M, Riou B. Early and delayed myocardial infarction after abdominal aortic surgery. *Anesthesiology*. 2005;102(5):885-891.
8. Mazumdar M, Smith A, Bacik J. Methods for categorizing a prognostic variable in a multivariable setting. *Stat Med*. 2003;22(4):559-571.
9. Hougaard P. *Shared Frailty Models. Analysis of Multivariate Survival Data: Statistics for Biology and Health*. New York, NY: Springer; 2000:215-262.
10. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. *J Natl Cancer Inst*. 2003;95(18):1404-1413.
11. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. *Am J Epidemiol*. 1985;122(5):904-914.
12. Parzen M, Lipsitz SR. A global goodness-of-fit statistic for Cox regression models. *Biometrics*. 1999;55(2):580-584.
13. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. *Lifetime Data Anal*. 1998;4(2):109-120.
14. Kremers WK. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Rochester, MN: Mayo Clinic; 2007. Technical Report Series #80.
15. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker. *Stat Med*. 2008;27(2):157-172.
16. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease. *Kidney Int*. 2005;67(6):2089-2100.
17. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612.
18. Derksen S, Keselman H. Backward, forward and